Lung cancer remains the leading cause of cancer-related death worldwide, and clinical development is shifting faster than at any point in the past decade. The central challenge is that precision medicine, novel therapeutic modalities, and increasingly sophisticated trial designs are reshaping what is possible for patients while raising the operational bar for sponsors competing for narrow, biomarker-defined populations.
As newer modalities join checkpoint inhibitors, programs must balance scientific ambition with the executional realities of fragmented patient pools, complex assay strategies, and the regulatory nuance of modern adaptive designs. This article examines where the field is heading and what it takes to run a competitive lung cancer program in that environment, to understand how to translate scientific progress into operational execution.
Read the full article to learn about:
- Why antibody-drug conjugates (ADCs) and bispecific antibodies represent a turning point in non-small cell lung cancer (NSCLC), and what the latest Phase III data signal for sponsors
- The biomarker validation challenge, from the limits of PD-L1 scoring to emerging predictors such as circulating tumor DNA (ctDNA), spatial immune architecture, and STK11/KEAP1 co-mutations
- Why the Asia-Pacific (APAC) region is strategically critical for lung cancer research, including its disproportionate share of early-onset and never-smoker NSCLC
- The protocol-level decisions, including site selection, companion diagnostic development, and sample collection, that determine whether a biomarker-driven program is feasible at scale
